CEL-SCI Corporation to Present at The MicroCap Conference
April 09 2018 - 9:45AM
Business Wire
CEL-SCI Corporation (NYSE American: CVM), a Phase 3
cancer immunotherapy biopharmaceutical company, announces today
that Geert Kersten, Chief Executive Officer, will present a
corporate overview at The MicroCap Conference on Tuesday, April
10th at 10 a.m. Eastern time. The conference will be held April
9-10, 2018 at the Essex House in New York City.
Mr. Kersten’s presentation will be available in the Investor
Relations section of the Company's website at
www.cel-sci.com/investor_relations.html.
About The MicroCap Conference
The MicroCap Conference is an exclusive event dedicated to
connecting high-performing small and microcap companies with
committed investors. It is an opportunity to be introduced to and
speak with management at some of the most attractive companies,
learn from various expert panels, and network with other small and
microcap investors.
About CEL-SCI Corporation
CEL-SCI is a Phase 3 cancer immunotherapy company. The Phase 3
study is fully enrolled with 928 patients. When it comes to cancer
immunotherapy, CEL-SCI believes it is most logical to boost the
patient’s immune system while it is still intact in order to have
the greatest possible impact on survival. Therefore, CEL-SCI treats
patients who are newly diagnosed with head and neck cancer with its
lead investigational immunotherapy Multikine (Leukocyte
Interleukin, Injection), BEFORE they have received surgery,
radiation and/or chemotherapy. This approach is unique. Most other
cancer immunotherapies are used only after conventional therapies
have been tried and/or failed. Head and neck cancer represents
about 6% of all cancers. Multikine has received Orphan Drug
designation from the FDA for the treatment of head and neck cancer
patients with advanced squamous cell carcinoma. CEL-SCI has
received patents for Multikine from the US, Europe, China and
Japan.
The Company’s LEAPS technology is being developed as a
therapeutic vaccine for rheumatoid arthritis and is supported by
grants from the National Institutes of Health. The Company has
operations in Vienna, Virginia, and in/near Baltimore,
Maryland.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180409005827/en/
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Sep 2023 to Sep 2024